$CLLS

Cellectis (ALCLS) shared expanded preclinical data for its APOC3 base editor, .HEAL-101, and announced plans to initiate a Phase 1 investigator-initiated trial in China, with preliminary data expected in the second half of 2027.

Cellectis (Nasdaq: CLLS) presented preclinical data for its .HEAL-101 gene therapy, showing 70% in vivo editing of human APOC3 and 76% triglyceride reduction in mice. The company plans a Phase 1 trial in China, with preliminary data expected in 2027. Cellectis aims to develop a one-time treatment for severe hypertriglyceridemia.

Cellectis SA (CLLS) shares dropped 14.6% after Barclays downgraded the stock to Underweight, cutting its price target to $1.30 from $9.00. Analyst Lukas Shumway cited lack of conviction in Cellectis' new programs, assigning negative net present values to .HEAL-101 and .HEAL-201. The valuation model now includes $2 each for Royalties and Milestones, -$1 for Debt, and $5 for Cash, assuming a capital raise in late 2027.

Analysts made several rating changes: Wolfe upgraded Paychex (PAYX) citing stable employment trends. UBS upgraded Union Pacific (UNP) to Buy with a $339 price target, expecting strong 2027 volume growth. Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 target after FDA reaffirmed study design. JPMorgan upgraded Credicorp (BAP) to Overweight with a $482 target, seeing strong EPS growth. Morgan Stanley downgraded Expedia (EXPE) to Underweight with a $235 target, citing weaker assets

Analysts downgraded several stocks: HSBC cut Banco Santander Brasil (BSBR) to Hold with a $6.2 target; Rosenblatt downgraded Ribbon Communications (RBBN) to Neutral with a $2.2 target; Citizens downgraded Cellectis (CLLS) to Market Perform; Barclays downgraded Scholar Rock (SRRK) to Equal-Weight with a $58 target; Raymond James downgraded Ascendis Pharma (ASND) to Outperform with a $287 target.

Cellectis (CLLS) reported Q2 2026 cash, cash equivalents and fixed-term deposits of $169M as of June 30, 2026, versus $145M in Q2 2025, citing runway into Q4 2027. At EHA 2026, lasme-cel in BALLI-01 moved to pivotal Phase 2 after FDA RMAT (June 2026), with ORR 67% and CR 56% in Phase 1. Eti-cel in NATHALI-01 showed ORR 46% and CR 31%.

Cellectis held its general shareholders meeting in Paris on June 25, 2026, with about 55.84% of voting rights represented. According to the company, resolutions 1–29 were adopted and resolution 30 was rejected, in line with the board’s recommendations. Voting results and resolution details are posted on Cellectis’ website.

Cellectis said the FDA granted RMAT designation to lasme-cel, its CD22-targeting allogeneic CAR-T candidate, for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The company cited Phase 1 BALLI-01 data for efficacy and a manageable safety profile. Final Phase 1 results are scheduled for presentation at EHA on June 13; BALLI-01 Phase 2 enrollment is open.

Cellectis S.A., a clinical-stage biotechnology company, announced that its annual general meeting of shareholders will take place on June 25, 2026, at the Biopark auditorium in Paris at 2:30 p.m. CET. The company, which specializes in gene-edited CAR T-cell therapies, provides details and materials for the meeting on its website. TipRanks' AI Analyst, Spark, rates CLLS as Neutral due to weak financial performance marked by ongoing losses and rising leverage, despite moderately supportive technical indicators.

Cellectis S.A., a clinical-stage biotechnology company, announced it will release its first-quarter 2026 financial results on May 11, 2026, after the U.S. market close. The company will issue a press release on its website but will not host a conference call, directing investors to its investor relations team for inquiries. Currently, analyst ratings for CLLS stock lean towards a "Buy" with a $9.00 price target, while TipRanks' AI Analyst, Spark, rates it as "Neutral" due to financial performance concerns.